The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: Systematic review, network meta-analysis and health economic evaluation

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Loveman, Emma ^a   Copley, Vicky R ^a   Colquitt, Jill L ^a   Scott, David A ^b   Clegg, Andy J ^a   Jones, Jeremy ^a   O'Reilly, Katherine ^c   Singh, Sally ^d   Bausewein, Claudia ^e   Wells, Athol ^f  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ICON PLC   (United Kingdom)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Green Lanes Surgery   (United Kingdom)

Author keywords

Cost effectiveness; Idiopathic pulmonary fibrosis; Meta analysis; Systematic review

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; NINTEDANIB; PIRFENIDONE; PREDNISOLONE; SILDENAFIL; THALIDOMIDE; PLACEBO; PREDNISONE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; META ANALYSIS; NATIONAL HEALTH SERVICE; PALLIATIVE THERAPY; PULMONARY REHABILITATION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; DISEASE SEVERITY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICE; HOSPITALIZATION; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MONOTHERAPY; MUSCLE TRAINING; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84924361457     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-63     Document Type: Article

References (35)

1. Swigris JJ, Stewart AL, Gould MK, Wilson SR: Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005, 3:61.10.1186/1477-7525-3-61.
2. Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8. http://www.ojrd.com/content/3/1/810.1186/1750-1172-3-8.
3. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011, 66:462-467.10.1136/thx.2010.148031.
4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:810-816.10.1164/rccm.200602-163OC.
5. NICE: Diagnosis and management of suspected idiopathic pulmonary fibrosis. CG 163. London: NICE; 2013.
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.10.1164/rccm.2009-040GL.
7. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI: The registry of the international society for heart and lung transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2013, 31:1073.
8. Centre for Reviews and Dissemination: Systematic reviews: CRD's guidance for undertaking reviews in health care. Third edition. York: York Publishing Services Ltd., CRD; 2009.
9. Drummond MF, Jefferson TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ 1996, 313:275-283.10.1136/bmj.313.7052.275.
10. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J: Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004, 8:1-158.
11. Higgins JP, Green S: Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. Cochrane Collaboration 2011. Available from http://www.cochrane-handbook.org
12. Caldwell D, Ades AE, Higgins JPT: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.10.1136/bmj.331.7521.897.
13. Dias S, Welton NJ, Sutton AJ, Ades AE: NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. http://www.nicedsu.org.uk.14-6-0013
14. Chinn S: A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000, 19:3127-3131.10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M.
15. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.10.1016/S0140-6736(11)60405-4.
16. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.10.1056/NEJMoa1103690.
17. Hagaman JT, Kinder BW, Eckman MH: Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010, 188:125-132.10.1007/s00408-009-9217-8.
18. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.10.1183/09031936.00005209.
19. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.10.1164/rccm.200404-571OC.
20. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242.10.1056/NEJMoa042976.
21. Raghu G, Anstrom KJ, King J, Lasky JA, Martinez FJ: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977.
22. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S: Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012, 17:467-477.10.1111/j.1440-1843.2012.02132.x.
23. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991, 144:291-296.10.1164/ajrccm/144.2.291.
24. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363:620-628.
25. Horton MR, Santopietro V, Matthew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N: Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med 2012, 157:398-406.10.7326/0003-4819-157-6-201209180-00003.
26. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishimura K, Taniguchi H: Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008, 13:394-399.10.1111/j.1440-1843.2007.01205.x.
27. Lindell KO, Olshansky E, Song MK, Zullo TG, Gibson KF, Kaminski N, Hoffman LA: Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010, 39:304-313.10.1016/j.hrtlng.2009.08.005.
28. Jastrzebski D, Kozielski J, Zebrowska A: [Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis with inspiratory muscle training]. [Polish]. Pneumonol Alergol Pol 2008, 76:131-141.
29. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM: Long-term course and prognosis of idiopathic pulmonary fibrosis in the New millennium. Chest 2011, 140:221-229.10.1378/chest.10-2572.
30. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, Collard HR: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012, 67:407-411.10.1136/thoraxjnl-2011-201184.
31. Anyanwu AC, McGuire A, Rogers CA, Murday AJ: Assessment of quality of life in lung transplantation using a simple generic tool. Thorax 2001, 56:218-222.10.1136/thorax.56.3.218.
32. Department of Health: National health service England and wales electronic drug tariff May 2013. 2013. 14-6-2013. http://www.ppa.org.uk/edt/May_2013/mindex.htm
33. Joint Formulary Committee: British national formulary (BNF) 65. No. 65. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2013.
34. Department of Health: NHS reference costs 2011-2012. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012. 8-11-2012
35. Mills EJ, Thorlund K, Ionnidis JPA: Demystifying trial networks and network meta-analysis. BMJ 2013, 346:f2914.10.1136/bmj.f2914.